Last Updated:
4:10 pm
Tuesday, August 5, 2025
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
asx-cuv
Market Cap
AU$510.26M
Volume
56492
Open
12.75
AU$
High
12.75
AU$
Low
12.18
AU$
Shares On Issue
50M
52 Week Low
9.41
AU$
52 Week High
15.99
AU$
Website
www.clinuvel.com
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved